NCT07300475 2026-02-13
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
Washington University School of Medicine
Phase 1 Not yet recruiting
Clinical Trials
8 trialsNCT07283692 2026-02-03
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
RenJi Hospital
Phase 2 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT06492759 2025-12-16
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Emory University
Phase 2 Not yet recruiting
NCT07187674 2025-09-23
The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
Harbin Medical University
Phase NA Not yet recruiting
NCT06407310 2024-05-09
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
Tel Aviv Medical Center
Phase 2 Not yet recruiting
NCT06371807 2024-04-17
KEYPARTNER
Fundacao Champalimaud
Phase 2 Not yet recruiting
NCT05067530 2021-10-05
CAREGIVER
Medical University of Gdansk
Phase 2 Not yet recruiting